Phosphodiesterase‐5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury
Abstract
Traumatic cerebrovascular injury (TCVI), a common consequence of traumatic brain injury (TBI), presents an attractive therapeutic target. Because phosphodiesterase‐5 (PDE5) inhibitors potentiate the action of nitric oxide (NO) produced by endothelial cells, they are candidate therapies for TCVI. This study aims to: (1) measure cerebral blood flow (CBF), cerebrovascular reactivity (CVR), and change in CVR after a single dose of sildenafil (ΔCVR) in chronic TBI compared to uninjured controls; (2) examine the safety and tolerability of 8‐week sildenafil administration in chronic symptomatic moderate/severe TBI patients; and as an exploratory aim, (3) assess the effect of an 8‐week course of sildenafil on chronic TBI symptoms.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 07, 2018
- Source ID
- 10.1002/acn3.541
Entities
People
- Bao‐ Xi Qu
- Carol Moore
- Christian Shenouda
- Eric M Wassermann
- Erika Silverman
- Franck Amyot
- Hanzhang Lu
- Kimbra Kenney
- L Christine Turtzo
- Leah Harburg
- Margalit Haber
- Ramon Diaz‐arrastia
- Yunhua Gong
Organizations
- Johns Hopkins University
- National Institutes of Health
- Uniformed Services University of the Health Sciences
- University of Pennsylvania